3 trillion yuan of Chinese medicine market size, who can undertake this good?

"
Pharmaceutical Network Market Analysis: Since 2020, Chinese medicine has received more attention, the local also introduced a series of policies to support the innovation and development of Chinese medicine, the industry generally believes that in this context, the Chinese medicine industry ushered in a good opportunity for developmentData predict that the size of China's traditional Chinese medicine market will reach 3 trillion yuan by 2020However, not all Chinese medicine enterprises can undertake this goodpharmaceutical strategy consultant told the media, can undertake this good must be the product with accurate efficacy, safety and security of the Chinese medicine enterprises, and with the gradual elimination of health care is useless and sales of large varieties, Chinese medicine enterprises will also usher in the industry reshuffle, to promote enterprises of good new drug research and development and industry resources merger and acquisition integration more activein fact, the Chinese medicine industry's reshuffle is already intensifyingTaking Chinese medicine injections as an example, as one of the key objects of medical reform, in recent years, more and more Chinese medicine injection varieties are facing the fate of being included in the key monitoring catalogue, or are removed from the medical insurance catalogueSales of Chinese medicine injections at the end of China's public medical institutions fell by 8.54% in 2018, according to Minnet.comrelated Chinese medicine injection production enterprises, especially as the main varieties of pharmaceutical enterprises have also naturally been affectedFor example, China Resources 39 ginseng injections, vein injections, etcwere included in the local key monitoring varieties, related products sales have been continued to declineAlthough this year, ginseng, raw veins, ginseng injections were included in the National Health and Care Commission's diagnosis and treatment program recommended drugs, but from the first quarter of 2020 report, also failed to save the decline in China Resources 39 profits;at the same time, the Chinese medicine industry resources merger sandaling is more frequentFor example, in January, China Resources completed the acquisition of a 100% stake in Aono Pharmaceuticals, enriching the layout of its products in the field of children's health, and at the end of April, the board approved a stake in a high-end inhaling preparation generic selling company that will acquire the right to sell a respiratory drug product in China in the future, according to the investor relations activity records released by China ResourcesAt the same time, in the field of health care products and the Japanese OTC market also has a number of cooperation the author learned that at present, there are many Chinese medicine enterprises have opened the road of transformation For example, Xiang Xue Pharmaceutical sane 2020 quarterly report disclosed that the company has five products in research, involving cancer, immunity and other fields, there are other Chinese medicine enterprises product line expanded to chemical drugs, antibiotics, biochemical drugs, biological products and other fields industry believes that, in general, with the two-vote system, medical expenses growth control, restriction sedative strain, medical insurance payment price adjustment, health insurance catalog to cost-effective innovative drugs tilt, drug centralized procurement and other series of policies to promote, for many Chinese medicine enterprises is a shock, will also bring about changes in the competitive landscape of the Chinese medicine industry In this context, only with clinical value, safe and secure products, in order to shuffle in the market to establish a foothold in addition, with the clinical drug use more and more standardized, medical insurance cost control more and more strict, in the safe and effective clinical value to obtain market share of the normative development stage, Chinese medicine enterprises technology research and development and product strategy need to be transformed and upgraded .